secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0000950170-25-097078
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Bio raises $175M in oversubscribed private placement; Sanofi participates; cash runway into mid-2028
--------------------------------------------------------------------------------

- Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.
- Investors include strategic partner Sanofi, RA Capital, Commodore Capital, Vivo Capital, Blackstone Multi-Asset, and others.
- Proceeds to fully fund Phase 2b SAFEGUARD study of SAB-142 in Stage 3 T1D and extend cash runway into middle of 2028.
- Warrants exercisable for up to 1.5M additional preferred shares, potentially yielding additional $284M in gross proceeds.
- Company received FDA alignment on Phase 2b SAFEGUARD trial design during a Type B meeting on May 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025097078/0000950170-25-097078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025097078/sabs-20250721.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-097078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer